Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management.
Ver gráficos interactivos y estados completos →
| Cuenta de resultados | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Ingresos totales | ₹54.1B | ₹45.9B | ₹41.6B | ₹37.1B | — |
| Beneficio bruto | ₹41.6B | ₹34.6B | ₹30.5B | ₹25.9B | — |
| Ingresos operativos (EBIT) | ₹13.3B | ₹11.3B | ₹10.5B | ₹6.8B | — |
| Ingresos netos | ₹10.6B | ₹9.2B | ₹8.2B | ₹5.9B | — |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de AJANTPHARM. /companies/us/AJANTPHARM
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms